Cancer Pharmacology

An Illustrated Manual of Anticancer Drugs

Ashkan Emadi (Redaktør) ; Judith E. Karp (Redaktør)

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs provides a one-stop guide to the essential basic and clinical science of all the effective, life-prolonging drug therapies in oncology. From traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents, this book covers the staggering advances in cancer pharmacology that are propelling new standards of care for common and uncommon malignancies. Les mer
Vår pris
1315,-

(Paperback) Fri frakt!
Leveringstid: Sendes innen 21 dager
På grunn av Brexit-tilpasninger og tiltak for å begrense covid-19 kan det dessverre oppstå forsinket levering.

Paperback
Legg i
Paperback
Legg i
Vår pris: 1315,-

(Paperback) Fri frakt!
Leveringstid: Sendes innen 21 dager
På grunn av Brexit-tilpasninger og tiltak for å begrense covid-19 kan det dessverre oppstå forsinket levering.

Om boka

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs provides a one-stop guide to the essential basic and clinical science of all the effective, life-prolonging drug therapies in oncology. From traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents, this book covers the staggering advances in cancer pharmacology that are propelling new standards of care for common and uncommon malignancies. Beautifully illustrated throughout, each chapter contains visually engaging figures detailing the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic, and molecular properties of the various agents, and their mechanisms of action. As the first illustrated book of its kind, this highly visual text uses a uniform approach to each cancer drug class and agent presented in the book, and covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Flow diagrams, clinical tables, and bulleted text further explain important information pertaining to each cancer drug class including their indications, mechanisms of action, potential adverse reactions, dosing and dose adjustments, and safety monitoring. Organized in an easy-to-digest format and replete with detailed images, clinical pearls, and end of chapter Q&As, this evidence-based reference presents all major classes, agents, targets, and approaches to cancer pharmacotherapy.Whether you are a trainee, a clinical scientist, or a clinician in practice, the book is an ideal reference. It presents challenging information in an instructional way; it illustrates key concepts for ease of retention; and, it poses tough questions so readers can problem solve potential scenarios and test their pharmacologic acumen. Written by leading experts in oncopharmacology, this first-of-its kind manual is a "must have" for anyone involved in the basic, translational, or clinical aspects of oncology and hematology including clinicians, pharmacists, nurses, and trainees.

Key Features:



Includes visual depictions of chemical structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents
Describes how chemotherapy, targeted therapy, immunotherapy, hormonal therapy, work and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other modalities
Over 135 highly stylized images and numerous comprehensive tables
Covers challenges related to drug development, drug approval and regulatory issues in relation to anticancer treatments
All chapters conclude with clinical pearls and detailed clinical Q&As with descriptive rationales
Purchase includes access to the ebook for use on most mobile devices or computers

Fakta

Innholdsfortegnelse

1. Anticancer Drug Development: An Introduction: Edward A. Sausville
2. Alkylating Agents: Ali Bukhari and Ashkan Emadi
3. Antimetabolites: Hydroxyurea, Pyrimidine and Purine Analogs, and L-Asparaginase: Crystal Lu, Judith E. Karp and Ashkan Emadi
4. Antimetabolites: Antifolates: Justin Lawson and Edward Sausville
5. Antimitotics: Edward A. Sausville
6. DNA Repair, Apoptotic Pathways, CDK Inhibitors: Mira A. Kohorst and Scott H. Kaufmann
7. Epigenetic Modulators: Lukasz P. Gondek
8. Differentiating Agents and Microenvironment: Gabriel Ghiaur
9. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer: Amy Fulton and Katherine H.R. Tkaczuk
10. Male Hormonal Therapies: Arif Hussain and Vincent Njar
11. Targeted Therapies (Small Molecules): Michael G. McCusker, Jr., Katherine A. Scilla, and Christian Rolfo
12. Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents: Alison Duffy and Ciera Patzke
13. Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors: Mark Yarchoan and Elizabeth Jaffee
14. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention: Mehmet Kocoglu
15. Transplant-Related Agents: Jean Yared and Saurabh Dahiya
16. Basic Drug Development with Structural Considerations: Sonia Esparza and Joshua Zeidner
17. Integral Components in Development of Clinical Trials: PK/PD, Statistics, and Principles of Rational Combinatorial Therapies: S. Percy Ivy and Richard F. Little
18. Drug Approval and Regulatory Issues: Olanrewaju O. Okusanya, Ruby Leong, Matthew D. Thompson, and Donna Przepiorka

Om forfatteren

Associate Professor of Medicine, Pharmacology and Experimental Therapeutics, Associate Program Director, Hematology & Medical Oncology Fellowship, University of Maryland, School of Medicine, Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland Professor Emerita, Oncology, and Medicine, The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Hematologic Malignancies, Baltimore, Maryland